Ana P Rossi1, Debra D Burris2, F Leslie Lucas3, Gail A Crocker4, James C Wasserman5. 1. Department of Nephrology and Transplantation, Maine Medical Center. 2. Clinical Trial Support Services, Maine Medical Center Research Institute. 3. Center for Outcomes Research and Evaluation, Maine Medical Center Research Institute, and. 4. Turning Point Cardiac Rehabilitation & Prevention, Maine Medical Center, Portland, Maine. 5. Department of Nephrology and Transplantation, Maine Medical Center, wassej@mmc.org.
Abstract
BACKGROUND AND OBJECTIVES:Patients with CKD have a high prevalence of cardiovascular disease associated with or exacerbated by inactivity. This randomized, controlled study investigated whether a renal rehabilitation exercise program for patients with stages 3 or 4 CKD would improve their physical function and quality of life. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In total, 119 adults with CKD stages 3 and 4 were randomized, and 107 of these patients proceeded to usual care or the renal rehabilitation exercise intervention consisting of usual care plus guided exercise two times per week for 12 weeks (24 sessions). Physical function was determined by three well established performance-based tests: 6-minute walk test, sit-to-stand test, and gait-speed test. Health-related quality of life was assessed by the RAND 36-Item Short Form Health Survey. RESULTS: At baseline, no differences in self-reported level of activity, 6-minute walk test, and sit-to-stand test scores were observed between the usual care (n=48) and renal rehabilitation exercise (n=59) groups, although baseline gait-speed test score was higher in the renal rehabilitation exercise group (P<0.001). At follow-up, the renal rehabilitation exercise group but not the usual care group showed significant improvements in the 6-minute walk test (+210.4±266.0 ft [19% improvement] versus -10±219.9 ft; P<0.001), the sit-to-stand test (+26.9±27% of age prediction [29% improvement] versus +0.7±12.1% of age prediction; P<0.001), and the RAND-36 physical measures of role functioning (P<0.01), physical functioning (P<0.01), energy/fatigue levels (P=0.01), and general health (P=0.03) and mental measure of pain scale (P=0.04). The renal rehabilitation exercise regimen was generally well tolerated. CONCLUSIONS: A 12-week/24-session renal rehabilitation exercise program improved physical capacity and quality of life in patients with CKD stages 3 and 4. Longer follow-up is needed to determine if these findings will translate into decreased mortality rates.
RCT Entities:
BACKGROUND AND OBJECTIVES:Patients with CKD have a high prevalence of cardiovascular disease associated with or exacerbated by inactivity. This randomized, controlled study investigated whether a renal rehabilitation exercise program for patients with stages 3 or 4 CKD would improve their physical function and quality of life. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In total, 119 adults with CKD stages 3 and 4 were randomized, and 107 of these patients proceeded to usual care or the renal rehabilitation exercise intervention consisting of usual care plus guided exercise two times per week for 12 weeks (24 sessions). Physical function was determined by three well established performance-based tests: 6-minute walk test, sit-to-stand test, and gait-speed test. Health-related quality of life was assessed by the RAND 36-Item Short Form Health Survey. RESULTS: At baseline, no differences in self-reported level of activity, 6-minute walk test, and sit-to-stand test scores were observed between the usual care (n=48) and renal rehabilitation exercise (n=59) groups, although baseline gait-speed test score was higher in the renal rehabilitation exercise group (P<0.001). At follow-up, the renal rehabilitation exercise group but not the usual care group showed significant improvements in the 6-minute walk test (+210.4±266.0 ft [19% improvement] versus -10±219.9 ft; P<0.001), the sit-to-stand test (+26.9±27% of age prediction [29% improvement] versus +0.7±12.1% of age prediction; P<0.001), and the RAND-36 physical measures of role functioning (P<0.01), physical functioning (P<0.01), energy/fatigue levels (P=0.01), and general health (P=0.03) and mental measure of pain scale (P=0.04). The renal rehabilitation exercise regimen was generally well tolerated. CONCLUSIONS: A 12-week/24-session renal rehabilitation exercise program improved physical capacity and quality of life in patients with CKD stages 3 and 4. Longer follow-up is needed to determine if these findings will translate into decreased mortality rates.
Authors: Roger A Fielding; Jeffrey Katula; Michael E Miller; Kari Abbott-Pillola; Alexander Jordan; Nancy W Glynn; Brett Goodpaster; Michael P Walkup; Abby C King; W Jack Rejeski Journal: Med Sci Sports Exerc Date: 2007-11 Impact factor: 5.411
Authors: Jill Crandall; David Schade; Yong Ma; Wilfred Y Fujimoto; Elizabeth Barrett-Connor; Sarah Fowler; Sam Dagogo-Jack; Reubin Andres Journal: J Gerontol A Biol Sci Med Sci Date: 2006-10 Impact factor: 6.053
Authors: Baback Roshanravan; Cassianne Robinson-Cohen; Kushang V Patel; Ernest Ayers; Alyson J Littman; Ian H de Boer; T Alp Ikizler; Jonathan Himmelfarb; Leslie I Katzel; Bryan Kestenbaum; Stephen Seliger Journal: J Am Soc Nephrol Date: 2013-04-18 Impact factor: 10.121
Authors: Erin J Howden; Rodel Leano; William Petchey; Jeff S Coombes; Nicole M Isbel; Thomas H Marwick Journal: Clin J Am Soc Nephrol Date: 2013-08-22 Impact factor: 8.237
Authors: Amit X Garg; Rita S Suri; Paul Eggers; Fredric O Finkelstein; Tom Greene; Paul L Kimmel; Alan S Kliger; Brett Larive; Robert M Lindsay; Andreas Pierratos; Mark Unruh; Glenn M Chertow Journal: Kidney Int Date: 2017-01-13 Impact factor: 10.612
Authors: Luke A Baker; Daniel S March; Thomas J Wilkinson; Roseanne E Billany; Nicolette C Bishop; Ellen M Castle; Joseph Chilcot; Mark D Davies; Matthew P M Graham-Brown; Sharlene A Greenwood; Naushad A Junglee; Archontissa M Kanavaki; Courtney J Lightfoot; Jamie H Macdonald; Gabriella M K Rossetti; Alice C Smith; James O Burton Journal: BMC Nephrol Date: 2022-02-22 Impact factor: 2.388
Authors: Sankar D Navaneethan; Ciaran E Fealy; Amanda C Scelsi; Susana Arrigain; Steven K Malin; John P Kirwan Journal: Am J Nephrol Date: 2015-10-24 Impact factor: 3.754